Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. 4,5 Here, we review ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today ...

Vaccines save millions of lives every year, but there is still an urgent need for more efficient vaccines. Strategies to combat serious outbreaks of viral infections are particularly important.

Nipocalimab is designed to block the immunoglobulin G (IgG) binding site on the neonatal Fc receptor (FcRn) to reduce serum levels of total IgG, including pathogenic IgG autoantibodies in gMG.

Albumin was chosen as a carrier as it is actively transported across the mucosal barrier by FcRn, a receptor found on mucosal epithelial cells. Upon intranasal delivery to several different mouse ...

Vaccines save millions of lives every year, but there is still an urgent need for more efficient vaccines that target pathogens transmitted through the respiratory tract and may cause fatal infections ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...